Dr. Wu Oct 2024 from Bio4.....
https://stocktwits.com/Bio4
______
Now go back to July, 2023 pdf publication:

Allogeneic immunity clears latent virus following
allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques

Authors
Helen L. Wu, Kathleen Busman-Sahay, Whitney C. Weber, ...,Benjamin J. Burwitz, Jeffrey J. Stanton, Jonah B. Sacha

ACKNOWLEDGMENTS
We thank Amgen, Inc. for providing Neupogen, Bristol Myers Squibb for providing Nulojix, Gilead Sciences, Inc. for providing TDF and FTC, ViiV Healthcare for providing DTG, Brandon Keele for providing the SHIV-AD8-EOM virus, William Sutton and Nancy Haigwood for providing SIVmac239 gp140 trimer, and the ONPRC research support and animal care staff for their
work with the study animals. We also wish to acknowledge the animals that contributed to this study and express our respect and gratitude for their invalu-able role in this research.

This work was supported by the National Institutes of Health grants AI112433 and AI129703 awarded to J.B.S. and P51 OD011092 awarded to the Oregon National Primate Research Center (ONPRC). The ONPRC Molecular Virology Support Core and Integrated Pathology Core pro-vided support services for this research. This work was also supported by The Foundation for AIDS Research (amfAR) grant 108832 awarded to J.B.S. with support from Foundation for AIDS Immune Research (FAIR).


Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jonah
Sacha (sacha@ohsu.edu).
______

Frwd to last Shareholder Letter:

As previously announced, CytoDyn will be partnering with the American Foundation for AIDS Research (amfAR) to sponsor the HIV LATCH study which will use leronlimab to protect CCR5+ donor immune cells from HIV infection while aiming for a cure in the setting of bone marrow transplantation provided to an HIV+ recipient.
_______

Dr. Sacha is everywhere & associations are outstanding.

A big difference it seems now is, his work is going from independently of Cytodyn funded R&D, to now directly naming Cytodyn & LL as partners, in the going forward trials.

The sweet spot is, it's 2 LATCH programs now for Cytodyn.

In the words of Syneos:
From lab to life.